This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to investigate a novel strategy for treating multi-infarct dementia (MID). The $431,750 award supports research to overexpress the CYP2C11 enzyme in peri-lesion astrocytes using an adeno-associated virus (AAV) approach, with the goal of enhancing cerebral blood flow and suppressing neuroinflammation to improve cognitive function in a mouse model of MID. The project, awarded to the partnership of Henry Ford Health and Michigan State University Health Sciences, will test the optimal dose of the CYP2C11-expressing AAV, evaluate the long-term effects, and validate the causal impact on cognitive function. This targeted approach seeks to provide a groundbreaking treatment for MID, the most prevalent form of vascular cognitive impairment and dementia, which currently lacks disease-modifying therapies.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $431.8k | 5/19/25 |